Women with HER2-overexpressing or triple negative breast cancer subtype that has relatively higher risk of local recurrence were less likely to receive breast reconstruction compared with HR+/HER2− or HR+/HER2+ patients. Here, ERBB2 is linked to triple-negative breast carcinoma.